

AbbVie Inc. (ABBV) - ANALYST REPORT

Executive Summary with Comprehensive Analysis

\$210.39 **-\$0.38 (-0.18%)** AS OF 2026-05-15

Strategy: Conservative Stop Loss (Fixed ATR-based)

■ QUICK DECISION

Action: HOLD | Confidence: LOW | Signal Strength: 0/7

EXECUTIVE SUMMARY - Essential Metrics

| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|--------------------------|-----------------------|---------------------|--------------------------|
| Current Price | \$210.39 | Market Cap | \$371.7B |
| Past Win Rate (Backtest) | 66.7% | Forward P/E | 13.0x |
| Past Total Return | +39.6% | Analyst Target | \$252.93 |
| RSI / Trend Strength | 55 / 17 | Upside to Target | +20.2% |
| MACD Signal | Bearish | Revenue Growth | +12.4% |
| Profit Factor | 2.43 | Institutional Own. | 76.9% |
| Position Entry | 2026-04-29 @ \$203.89 | Analyst Ratings | 21 Buy / 9 Hold / 1 Sell |
| Open Position Past P&L | +3.2% | | |

■ TECHNICAL ANALYSIS SUMMARY

| Indicator | Value | Signal |
|----------------------|----------|---------------------|
| EMA 20 | \$206.57 | Bullish |
| EMA 50 | \$209.97 | Bullish |
| RSI (14) | 55.3 | Neutral range |
| Trend Strength (ADX) | 16.9 | Weak/No trend (<20) |

■ CONSENSUS & INVESTMENT RATIONALE

| RATING | STRONG BUY |
|-----------------|-------------|
| Target Price | \$252.93 |
| Upside/Downside | +20.2% |
| Risk/Reward | 1.35:1 |
| Time Horizon | 6-12 months |

Investment Rationale: Our STRONG BUY rating is based on: (1) Technical backtest showing 66.7% win rate with +39.6% total return over backtest period, (2) +20.2% upside to analyst consensus target of \$252.93, (3) Moderate fundamental growth profile with +12.4% revenue growth, and (4) 76.9% institutional ownership indicating high conviction from professional investors.

Action: Maintain position with +3.2% unrealized gain. Watch for confluence signal to add.

Technical Signal: Confluence 0/7 (threshold: 5) | **Risk/Reward:** Neutral

■ KEY INSIGHT

The fixed stop strategy has proven effective (Win Rate: 66.7%, Avg Return: +9.2%), but patience is critical. Only enter on confirmed signals with proper risk management. Current technical confluence of 0 does not meet entry threshold of 5 - remain on sidelines. Fundamental backdrop shows -46% earnings growth with 77% institutional ownership, indicating strong conviction from professional investors.

■ INTELLIGENT STOP LOSS STRATEGY

| METRIC | VALUE | DETAILS |
|--------------------|----------|---------------------------------------|
| Current Price | \$210.39 | Latest market price |
| Buy Stop Loss | \$199.50 | Conservative 2.0x ATR (5.2% distance) |
| Position Stop Loss | \$199.50 | Hybrid 2.00x ATR (5.2% distance) |
| ATR (14-day) | \$5.44 | Volatility: 2.6% of price |
| ADX Strength | 16.9 | Weak/No Trend |

Status: Position up +3% - Adaptive strategy adjusts for momentum

ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong

■ Strategy Comparison: Conservative vs Hybrid

| METRIC | CONSERVATIVE (2.0x ATR) | HYBRID (Adaptive) |
|-------------------|-------------------------|-------------------|
| Past Win Rate | 67% | 58% |
| Past Total Return | +39.6% | +52.7% |
| Max Drawdown | -15.9% | -15.8% |
| Total Trades | 15 | 24 |
| Position | OPEN | OPEN |

Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit.

For the latest stock analysis, support, resistance and interactive charts, visit [Ultra Stock Analysis Pro](#)

■ ANALYST RATING CHANGES - COMPLETE HISTORY

All recent upgrades, downgrades, and price target changes (last 90 days)

| Firm | Action | From → To | Date |
|-------------------|------------|-------------------------|--------------|
| Guggenheim | REITERATED | Buy → Buy | May 01, 2026 |
| Cantor Fitzgerald | REITERATED | Overweight → Overweight | Apr 30, 2026 |
| Canaccord Genuity | INITIATED | Buy | Apr 21, 2026 |
| RBC Capital | INITIATED | Outperform | Feb 25, 2026 |
| Barclays | INITIATED | Overweight | Feb 20, 2026 |

Analyst Price Targets

Average Target: \$252.93 (+20.2% from current)

High Target: \$328.00 (+55.9%)

Low Target: \$184.00 (-12.5%)

Current Price: \$210.39

DETAILED ANALYSIS: BUY-SIDE PERSPECTIVE

In-Depth Portfolio Management Analysis

Expected Returns & Position Sizing

Based on backtest performance (Win Rate: 66.7%, Avg Return: +9.2%) and analyst consensus (Target: \$252.93, +20.2% upside), an **OVERWEIGHT** exposure may be considered. Risk/Reward ratio of 1.35:1 suggests moderate risk-adjusted returns. Current open position shows +3.2% unrealized gain, supporting hold decision.

Catalyst Calendar & Timing

Next Major Catalyst: Jul 30, 2026 earnings report

Seasonality: Historical analysis shows positive momentum in backtest period

Technical Setup: Neutral - waiting for confluence signal

Institutional Activity: 76.9% institutional ownership (Largest: Blackrock Inc.)

Short Interest: 1.3% of float - Moderate short interest

Liquidity Profile

Average Volume: 6.8M shares/day - Lower liquidity

Market Cap: \$371.7B - Large cap

Beta: 0.30 - Lower than market volatility

Execution Risk: Moderate for institutional-sized positions

SELL-SIDE PERSPECTIVE - Investment Research Analysis

Investment Thesis

AbbVie Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 13.0x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 32.2% shows strong profitability. **Fundamental Outlook:** Moderate Growth - Monitoring profitability amid revenue expansion

Valuation Analysis

Forward P/E: 13.0x

Trailing P/E: 103.1x

Price/Sales: 5.92x - Premium valuation

Price/Book: -55.85x

Enterprise Value: \$435.3B

EV/Revenue: 6.93x (vs industry avg)

Competitive Positioning & Market Share

Key Competitors: Various industry players

U.S. Market Share: 0% - Competitive player

Global Market Share: 0%

Competitive Advantages: Market position, Technology, Brand

Key Products: Core products and services

Institutional Sentiment & Ownership

Institutional Ownership: 76.9% - Very high institutional confidence

Largest Holder: Blackrock Inc. (150.7M shares)

Analyst Coverage: 31 analysts

Consensus: 21 Buy, 9 Hold, 1 Sell - Bullish sentiment

■ 7-DAY NEWS SENTIMENT ANALYSIS

Market Sentiment from Recent Financial News

| METRIC | VALUE | ANALYSIS |
|--------------------------|------------------|--|
| Overall Score | +5.0 / 10 | Bullish |
| Articles Analyzed | 10 | Last 7 days (top 5 shown per category) |
| Bullish Articles | 8 (80%) | Positive sentiment |
| Bearish Articles | 0 (0%) | Negative sentiment |
| Neutral Articles | 2 (20%) | Mixed/Neutral tone |

■ TOP BULLISH HEADLINES

1. How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results? (Zacks, May 15)

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance....

Source: <https://finance.yahoo.com/sectors/healthcare/articles/important-skyrizi-rinvoq-a>

2. ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook (Zacks, May 15)

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence....

Source: <https://finance.yahoo.com/sectors/healthcare/articles/ani-pharmaceuticals-rare-d>

3. Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value (Simply Wall St., May 15)

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected t...

Source: <https://finance.yahoo.com/markets/stocks/articles/upstart-holdings-leads-3-stock>

4. Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie? (Zacks, May 15)

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart....

Source: <https://finance.yahoo.com/sectors/healthcare/articles/pharma-giant-offers-better>

5. AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear (Simply Wall St., May 15)

AbbVie Inc.'s (NYSE:ABBV) stock was strong despite it releasing a soft earnings report last week. Our analysis.....

Source: <https://finance.yahoo.com/markets/stocks/articles/abbvies-nyse-abbv-soft-earning>

■ SENTIMENT INTERPRETATION

The news sentiment is **strongly bullish**, indicating positive market perception and favorable coverage. This suggests growing investor confidence and potential upward momentum. Consider this as a supporting factor for bullish positions, but verify with technical and fundamental analysis.

DEEP DIVE: COMPREHENSIVE RISK ASSESSMENT

Detailed Risk Factors and Mitigation Strategies

Key Risks & Mitigants

Company-Specific Risks:

- Competition
- Market conditions
- Regulatory changes

Technical Risk Factors:

- Win Rate: 66.7% (10 wins, 5 losses)
- Profit Factor: 2.43x (Avg Win 17.3% vs Avg Loss -7.1%)
- Current Confluence: 0 (Last: 4 on May 08) - No setup - awaiting signal
- Volatility (ATR 14): \$5.44 (2.6% of price) - Stop loss typically 2-3x ATR

Market Risk:

- Beta: 0.30 - Below-average market sensitivity
- Short Interest: 1.3% - Normal short activity

REFERENCE: APPENDIX A - Complete Technical Indicators

Comprehensive Technical Data for Quantitative Analysis

| Indicator | Value | Interpretation |
|----------------------|----------|-------------------------------|
| EMA 20 | \$206.57 | Short-term trend |
| EMA 50 | \$209.97 | Medium-term trend |
| EMA 200 | \$213.02 | Long-term trend |
| Relative Strength | 55.3 | Neutral range |
| MACD | -0.23 | Bearish |
| MACD Signal | -1.42 | Signal line |
| MACD Histogram | 1.19 | Bullish |
| Volatility (ATR 14) | \$5.44 | 2.6% of price |
| Trend Strength (ADX) | 16.9 | Weak/No trend (<20) |
| +DI | 31.1 | Positive directional movement |
| -DI | 16.6 | Negative directional movement |
| Stochastic %K | 79.3 | Neutral |
| Stochastic %D | 73.3 | Neutral |
| Bollinger Upper | \$213.00 | Resistance zone |
| Bollinger Middle | \$204.49 | Moving average |
| Bollinger Lower | \$195.98 | Support zone |
| VWAP | \$211.44 | Volume-weighted average |

REFERENCE: APPENDIX B - Complete Fundamental Metrics

Comprehensive Fundamental Data for Financial Analysis

| Category | Metric | Value | Interpretation |
|---------------|----------------------|----------|-----------------------------|
| Valuation | Market Cap | \$371.7B | Total market value |
| Valuation | Enterprise Value | \$435.3B | Total company value |
| Valuation | Forward P/E | 13.0x | Price to forward earnings |
| Valuation | Trailing P/E | 103.1x | Price to trailing earnings |
| Valuation | PEG Ratio | 0.58 | P/E relative to growth |
| Valuation | Price/Sales | 5.92x | Market cap to revenue |
| Valuation | Price/Book | -55.85x | Price to book value |
| Valuation | EV/Revenue | 6.93x | Enterprise value to revenue |
| Valuation | EV/EBITDA | 14.6x | Enterprise value to EBITDA |
| Performance | Revenue (TTM) | \$62.8B | Trailing 12-month revenue |
| Performance | Revenue Growth | +12.4% | Year-over-year growth |
| Performance | Earnings Growth | -46.2% | Earnings growth rate |
| Performance | EPS Growth (Next Yr) | +695.7% | Forward EPS growth estimate |
| Performance | Gross Profit | \$45.2B | Revenue minus COGS |
| Performance | Operating Income | \$21.2B | EBIT |
| Performance | Net Income | \$3.6B | Bottom line profit |
| Performance | Free Cash Flow | \$20.8B | Cash after capex |
| Performance | Operating Cash Flow | \$21.2B | Cash from operations |
| Profitability | Gross Margin | 72.0% | Gross profit margin |
| Profitability | Operating Margin | 32.2% | Operating efficiency |
| Profitability | Profit Margin | 5.8% | Net margin |
| Profitability | ROE | 0.0% | Return on equity |
| Profitability | ROA | 10.0% | Return on assets |
| Profitability | ROIC | N/A | Return on invested capital |
| Balance Sheet | Total Assets | \$0.0B | Total assets |
| Balance Sheet | Total Liabilities | \$0.0B | Total liabilities |
| Balance Sheet | Total Debt | \$72.9B | Total debt outstanding |
| Balance Sheet | Cash & Equivalents | \$9.4B | Liquid assets |
| Balance Sheet | Book Value/Share | -\$3.77 | Net worth per share |
| Balance Sheet | Current Ratio | 0.80 | Current assets/liabilities |
| Balance Sheet | Quick Ratio | 0.52 | Liquid assets/liabilities |
| Balance Sheet | Debt/Equity | 0.00 | Leverage ratio |
| Market | Beta | 0.30 | Market correlation |
| Market | 52-Week High | \$244.81 | Annual high |
| Market | 52-Week Low | \$180.25 | Annual low |

| | | | |
|-----------------|--------------------|--------------|----------------------|
| Market | Avg Volume | 6.8M | Average daily volume |
| Market | Shares Outstanding | 1.8B | Total shares |
| Market | Float | 1.8B | Tradeable shares |
| Market | Short Interest | 1.3% | Shares sold short |
| Market | Institutional Own. | 76.9% | Institution held |
| Analysts | Coverage Count | 29 | Number of analysts |
| Analysts | Average Rating | 1.8 | 1=Strong Buy, 5=Sell |
| Analysts | Buy/Hold/Sell | 21/9/1 | Rating distribution |
| Analysts | Target Price | \$252.93 | Average price target |
| Analysts | Target High | \$328.00 | Highest target |
| Analysts | Target Low | \$184.00 | Lowest target |
| Other | Next Earnings | Jul 30, 2026 | Earnings report date |
| Other | Dividend Yield | 3.29% | Annual dividend rate |
| Other | Ex-Dividend Date | 1776211200 | Next ex-div date |

REFERENCE: APPENDIX C - Complete Trade History

Detailed Backtesting Results and Trade Log

| Entry | Exit | Type | Entry \$ | Exit \$ | Past P&L % | Past P&L \$ |
|------------|------------|--------------|----------|----------|------------|-------------|
| 2019-08-07 | 2020-01-31 | CONFLUENCE | \$64.46 | \$81.02 | +25.7% | +\$1010 |
| 2020-02-07 | 2020-03-12 | CONFLUENCE | \$92.29 | \$78.61 | -14.8% | -\$752 |
| 2020-03-23 | 2021-07-30 | CONFLUENCE | \$64.50 | \$116.30 | +80.3% | +\$932 |
| 2021-09-07 | 2021-09-08 | CONFLUENCE | \$109.03 | \$110.36 | +1.2% | +\$56 |
| 2021-10-29 | 2023-01-23 | CONFLUENCE | \$114.67 | \$148.55 | +29.6% | +\$1931 |
| 2023-06-01 | 2023-08-16 | CONFLUENCE | \$133.44 | \$151.55 | +13.6% | +\$779 |
| 2023-10-19 | 2023-10-23 | CONFLUENCE | \$145.52 | \$144.73 | -0.5% | -\$43 |
| 2023-10-27 | 2023-12-07 | CONFLUENCE | \$138.93 | \$147.97 | +6.5% | +\$434 |
| 2023-12-12 | 2024-04-15 | GOLDEN_CROSS | \$153.24 | \$161.67 | +5.5% | +\$472 |
| 2024-04-26 | 2024-07-01 | CONFLUENCE | \$159.62 | \$170.37 | +6.7% | +\$419 |
| 2024-07-25 | 2024-11-13 | CONFLUENCE | \$182.17 | \$170.35 | -6.5% | -\$437 |
| 2025-01-22 | 2025-04-10 | CONFLUENCE | \$169.20 | \$174.20 | +3.0% | +\$195 |
| 2025-09-11 | 2025-09-22 | CONFLUENCE | \$220.22 | \$222.59 | +1.1% | +\$90 |
| 2025-09-30 | 2025-11-05 | CONFLUENCE | \$231.54 | \$216.77 | -6.4% | -\$532 |
| 2025-11-12 | 2026-01-21 | CONFLUENCE | \$233.23 | \$216.15 | -7.3% | -\$410 |
| 2026-04-29 | OPEN | CONFLUENCE | \$203.89 | OPEN | +3.2% | +\$156 |

IMPORTANT DISCLAIMER

Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Ultra Stock Analysis Pro is not a registered investment advisor; information is impersonal and not tailored to individual circumstances. AI-generated content may contain errors — verify before acting. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-05-15. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.

Next Earnings: Jul 30, 2026

Report Generated: May 16, 2026 at 12:29 PM